Limited sponsorship opportunities are available. Platinum sponsorship includes an opportunity to join the speaker platform. Contact us to receive further details.
SynbiTECH 2019 has been created by Synthetic Biology experts and is committed to attracting the brightest and the best in the field.
If increasing your company's brand visibility amongst this community is a strategic part of your marketing plan, then our sponsorship packages have been tailored to enable maximum exposure in both virtual and real worlds.
We have several sponsorship and exhibitor packages designed to suit a broad range of budgets. Our expert communications team will provide advice to ensure your company utilises both SynbiTECH channels and your own business communication channels, to enable you make the most of the opportunity.
Please follow the link below to contact Dr John Collins, who will work with you to identify the package that is most suitable for your business.
At Twist Bioscience, we work in service of customers who are changing the world for the better. In fields such as medicine, agriculture, industrial chemicals and data storage, by using our synthetic DNA tools, our customers are developing ways to better lives and improve the sustainability of the planet.
Accelerating customer success
The faster our customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts.
We have created a revolutionary silicon-based DNA synthesis platform, that offers precision at a scale otherwise unavailable to our customers.
Innovative silicon-based DNA Synthesis Platform enables the production of high-quality synthetic DNA faster and more affordable than ever before
Platform technology overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis
Quality and quantity of our synthetic biology tools help researchers rapidly realize opportunities ahead
Analytik Jena is a leading manufacturer of analytical measuring technology, liquid handling and associated Life Science instrumentation and chemistries supporting many applications including Synthetic Biology. Their renowned CyBio FeliX liquid handling platforms and automation systems are chosen by Synthetic Biology labs worldwide to integrate pipetting and associated tasks from gene assembly through cloning, clean ups and transformations. Analytik Jena´s products are continually developed to offer customers ease of use, quality and reproducibility of their laboratory results. Quality service support, as well as device-specific consumables and reagents, complete the product portfolio. Analytik Jena is part of the Endress+Hauser Group.
Integrated DNA Technologies, Inc. (IDT) is your Advocate for the Genomics Age. For more than 30 years, IDT's innovative tools and solutions for genomics applications have been driving advances that inspire scientists to dream big and achieve their next breakthroughs.
IDT develops, manufactures, and markets nucleic acid products that support the life sciences industry in the areas of academic and commercial research, agriculture, medical diagnostics, and pharmaceutical development. We have a global reach with personalized customer service. https://www.idtdna.com/pages
World leaders in disruptive innovation & technology-based consulting
We specialise in helping our clients achieve the seemingly impossible.
From large multinationals to innovative start-ups, our clients trust us to solve their most critical, high-risk challenges. Through our combination of exceptional people, proven processes and world-class facilities, we deliver lasting impact.
Getting to market faster with superior product and service designs, we enable our clients to disrupt their markets and make high returns on their R&D investment.
m2p-labs microbioreactors (BioLector®) provide intelligent, online monitored micro fermentation technology for screening and scale-up bioprocess development, thus increasing the number of microbial experiments (aerobic/microaerophilic/strict anaerobic) as well as the information content. The microbioreactor system combined with a standard liquid handling robot (RoboLector®) allows automated fermentation of the whole bioprocess.
GenScript is the world leader in biotechnology reagent service industry that provides life sciences services and products to 200,000 scientists in over 100 countries worldwide. Established in 2002 in New Jersey, United States, the company was the first to commercialize gene synthesis and successfully establish fully-integrated capabilities for custom peptide synthesis, protein expression and engineering, custom antibody development and engineering, synthetic biology, in vitro/in vivo pharmacology as well as a variety of catalogue products, industrial enzymes and microbial reagents.
After almost two decades of fast growth in developing biological reagents, in recent years the company has expanded its business into immunotherapy, CDMO, laboratory equipment and microbial industry to further fulfil its mission in making people and nature healthier through biotechnology. GenScript has also established open and innovative technology-driven platforms and GMP facilities for pre-clinical drugs discovery and pharmaceutical products development along with a completed industrial microbial research, development and industrialization platform for enzyme screening, genetic engineering, protein engineering, and fermentation process optimization and research application.
With global support from all customers worldwide and more than 2600+ employees, GenScript continues to strive for its vision as the most reliable biotech company in the world to make people and nature healthier.
The council provides leadership for the UK’s interests in the rapidly developing field of Synthetic Biology. It provides a visible point for strategic coordination between the funding agencies, the research community, industry, government sponsors and other stakeholders, including societal and ethical representatives.
BBSRC is part of UK Research and Innovation, a new body which works in partnership with universities, research organisations, businesses, charities, and government to create the best possible environment for research and innovation to flourish. We aim to maximise the contribution of each of our component parts, working individually and collectively. We work with our many partners to benefit everyone through knowledge, talent and ideas.
The Engineering and Physical Sciences Research Council (EPSRC) is the main funding body for engineering and physical sciences research in the UK. By investing in research and postgraduate training, we are building the knowledge and skills base needed to address the scientific and technological challenges facing the nation.
Our portfolio covers a vast range of fields from healthcare technologies to structural engineering, manufacturing to mathematics, advanced materials to chemistry. The research we fund has an impact across all sectors. It provides a platform for future UK prosperity by contributing to a healthy, connected, resilient, productive nation.
In association with
The Centre for Synthetic Biology & Innovation (CSynBI) was established as the first UK National Centre for synthetic biology by an EPSRC grant in 2009. This enabled the establishment of a core group of academics working in synthetic biology at Imperial College. Since this time, it has been highly successful with the academics in CSynBI producing a large number of publications in top journals, attracting significant levels of independent research funding, running inter-faculty undergraduate and MRes teaching programmes and training a significant number of PhD students and Post-Docs.
The UK Centre for Mammalian Synthetic Biology is a BBSRC/EPSRC/MRC Synthetic Biology Research Centre, hosted by the School of Biological Sciences at the University of Edinburgh. Our vision is to apply synthetic biology in mammalian systems to realise its full potential for human medicine.
With world-leading faculty members drawn from the Biological Sciences, Medicine, Engineering, Informatics and the Social Sciences, the Centre offers an exciting and collaborative research environment. It also embeds colleagues from the Scottish Centre for Regenerative Medicine, a centre of excellence for stem cell research, who are supervisors on several projects.
The University of Manchester’s, Synthetic Biology Research Centre for Synthetic Biology of Fine and Speciality Chemicals (SYNBIOCHEM), funded by BBSRC/EPSRC aims to develop new faster, more predictable and reliable “greener” routes to fine and speciality chemicals production. The Centre provides tools, technology platforms and SynBio ‘know-how’ to drive academic discovery and translate new knowledge and processes towards industrial exploitation. The technology will lead to new products and methods for drug development, such as new antibiotics, and agricultural chemicals and new materials for sustainable manufacturing.
OpenPlant is a joint initiative between the University of Cambridge, John Innes Centre and the Earlham Institute, funded by the BBSRC and EPSRC as part of the UK Synthetic Biology for Growth programme.
OpenPlant is: (i) developing new tools and methods for plant synthetic biology, (ii) providing mechanisms for open sharing of standardised resources, (iii) applying these tools to world-leading projects in trait development, and (iv) facilitating interdisciplinary exchange, outreach and international development. The initiative promotes interdisciplinary exchange, open technologies and responsible innovation for improvement of sustainable agriculture and conservation.
BrisSynBio is a BBSRC / EPSRC funded Synthetic Biology Research Centre. BrisSynBio is a multi-disciplinary research centre that focuses on the biomolecular design and engineering aspects of synthetic biology. BrisSynBio is part of the Bristol BioDesign Institute.
WISB delivers an integrated, internationally leading programme of research, innovation and training for synthetic biology. WISB is a BBSRC/EPSRC funded Synthetic Biology Research Centre (SBRC), supported through the UK Research Councils' Synthetic Biology for Growth programme.
The London BioFoundry provides a suite of state-of-the-art robotic equipment enabling automated end-to-end design, construction and validation of large gene constructs. It is designed to bridge the gap between academia and industry, accelerating developments in engineering biology technologies and allowing SynbiCITE’s partners to prototype new biologically-based chemicals, drugs and materials.
The SBRC-Nottingham is one of six synthetic biology research centres established by the UK Research councils BBSRC and EPSRC.
Our centre concentrates on engineering bacteria to make industrially-useful products from C1-feedstocks including the greenhouse gases, carbon monoxide and carbon dioxide and methane.
BioPartner UK is the accredited trade organisation that provides practical support and international promotion to UK Life Sciences companies, who wish to grow their business overseas. BioPartner signposts to UK expertise and leads delegations to promote the UK presence at major international biopharma conferences. By operating in partnership with the UK government and event organisers, BioPartner assists all UK companies with access to government grants and heavily discounted entry fees. Members of the BioPartner Programme receive extra benefits and support to effectively trade overseas.
MediWales is the life science network for Wales. We are a not for profit, independent membership organisation, providing advice, support and business opportunities for our members. We have over 180 members including life science organisations, pharmaceutical services, medical technology companies, academia and the Welsh NHS. At Connects 2019 on the 2nd July, NHS colleagues from across Wales, local companies and the wider industry sector will join to share clinical innovation in practice to improve patient outcomes. The event includes keynote presentations, CPD training seminars, workshops and an exhibition. www.mediwales.com/connects/
Since 2015 we have provided media, events and intelligence to the global bio-economy. There has never been a more exciting time to work in our industry. McKinsey & Company estimates that the worldwide production of bio-based products is projected to grow from approximately $203.3 billion in 2015 to $400 billion by 2020 and $487 billion by 2024.
We want to support this sustainable shift towards the circular economy and the proliferation of bio-based products, chemicals, materials and innovations. Our team do this through providing news, intelligence and networking opportunities to the industry through our news portal, Quarterly digital magazine, bespoke content creation, white paper and report writing and promotion, World Bio Markets (Amsterdam, March 2020), SynBio Markets (Berlin, November 2019), videos, webinars and more!
We are the Institution of Engineering and Technology (IET), a not-for-profit multidisciplinary professional engineering institution with 168,000 members worldwide. We publish Engineering Biology, a new open-access journal with a focus on the application of engineering science and practice to the design of biological devices and systems for a wide range of fields and application. We welcome papers from all stages of the design cycle, from the development of platform technology and techniques, to industrial and scaling processes, and new technical standards. www.theiet.org; www.ietdl.org/enb
Labiotech.eu is the leading digital media covering the European Biotech industry. Over 150,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Hope you'll enjoy reading our stories!
Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.